The short version of quality control fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
== Notable members == General Lloyd Austin (born 1953), Commanding General of XVIII Airborne Corps, Commanding General of CENTCOM, 28th Secretary of Defense Master Sergeant Roy P. Benavidez (Medal of Honor Recipient), Vietnam War General of the Army Omar Bradley Moffatt Burriss, politician from South Carolina Jason Crow, member of the US House of Representatives for Colorado's 6th congressional district Fashion critic/choreographer Bruce Darnell (born 1957) Louisiana governor John Bel Edwards (born 1966) LTG Michael Flynn (born 1958), former commander of the 313th Military Intelligence Battalion and Division G-2 Actor Dennis Franz (born 1944) Leonard A. Funk Jr. 508th P.I.R, WW2 Medal of Honor recipient and credited as the most highly decorated US Army Airborne soldier of the Second World War Lieutenant General James M. Gavin Colonel Chris Gibson (born 1964), former commander of the 2d Battalion, 325th Infantry Regiment, and later commander of the division's 2d Brigade Combat Team, former New York Congressman Melvin O. Handrich (Medal of Honor Recipient, Korean War; First Special Service Force and Company I, 508th Parachute Infantry in World War II) Mark T. Vande Hei (born 1966), Col (En) (ret.), prior engineer platoon leader in 3/325th Infantry Real life Goodfellas movie mobster, Henry Hill served as a cook in the Division from 1960 to 1963. Sean D. Jordan, judge Clint Lorance (born 1984), officer convicted of second-degree murder for battlefield deaths; pardoned Jacklyn H.
Both photos became symbolic of the suffering of victims of the Bhopal disaster, and Bartholomew went on to win the 1985 World Press Photo of the Year. Within a few days, trees in the vicinity became barren, and bloated animal carcasses had to be disposed of. 170,000 people were treated at hospitals and temporary dispensaries, and 2,000 buffalo, goats, and other animals were collected and buried. Supplies, including food, became scarce owing to suppliers' safety fears. Fishing was prohibited, causing further supply shortages. Lacking any safe alternative, on 16 December, tanks 611 and 619 were emptied of the remaining MIC by reactivating the plant and continuing the manufacture of pesticide. Despite safety precautions such as having water-carrying helicopters continually overflying the plant, this led to a second mass evacuation from Bhopal. The Government of India passed the "Bhopal Gas Leak Disaster Act" that gave the government rights to represent all victims, whether or not in India. Complaints of lack of information or misinformation were widespread. An Indian government spokesman said, "Carbide is more interested in getting information from us than in helping our relief work". Formal statements were issued that air, water, vegetation, and foodstuffs were safe, but people were warned not to consume fish. The number of children exposed to the gases was at least 200,000. Within weeks, the State Government established a number of hospitals, clinics, and mobile units in the gas-affected area to treat the victims. S. Ravi Rajan (Prof. Environmental Studies, U.C.
tRNAdb (updated and completely restructured version of Spritzls tRNA compilation) Archived 2011-07-19 at the Wayback Machine tRNA surprising role in breast cancer growth Archived 2023-12-03 at the Wayback Machine tRNA link to heart disease and stroke GtRNAdb: Collection of tRNAs identified from complete genomes HGNC: Gene nomenclature of human tRNAs Molecule of the Month © RCSB Protein Data Bank: Transfer RNA Aminoacyl-tRNA Synthetases Elongation Factors Rfam entry for tRNA
=== Filming and post-production === Principal photography commenced in September 2024 at Toho's Stage 9 in Tokyo, with additional location shoots in Shizuoka Prefecture from February to April 2025. Filming wrapped in April 2025 after a brief pause in December 2024 when Aoi had high fever, however, she returned to work after being discharged from the hospital. The production incorporated practical effects alongside CGI to modernize the gaseous transformations, drawing from the original's tokusatsu roots. Open casting calls for extras ran through March 2025, offering non-commercial memorabilia as incentives. The film's visual effects were handled by Shirogumi, under the same team as Godzilla Minus One (2023).
Sources: en.wikipedia.org
=== Emigration === In an interview with VICE News' Krishna Andavolu shortly after Bukele's inauguration, he said that he "share[s] the same concern President Trump [has with] immigration, but for different reasons [...] [Trump] doesn't want our people to go; I don't want our people to leave." In a 2021 interview on Fox News' Tucker Carlson Tonight, Bukele attributed mass emigration from Central America to the United States to the region's "lack of economic opportunity" and "lack of security" and described the level of emigration to the United States as "immoral". He argued that emigration strained the United States and impeded domestic efforts to improve living conditions in El Salvador.
The entire Half-Life for PlayStation 2 package achieved gold status on October 30, 2001, and the game was released on November 14, 2001, in North America, and in Europe on November 30. In October 2005, work was begun by a group of Ukrainian developers to port Decay over to Windows, as a modification for both the old World Opponent Network and current Steam versions of Half-Life. The port relied on the discovery of a method that allowed Decay's PS2 game files to be converted to Windows version of the game. The port went into the beta development stage in December 2007 and was released publicly on September 23, 2008. The port was received well by the journalists in the industry; GameSpy site Planet Half-Life noted that it was a shame that an official PC version of Decay never emerged, while British journalist Alec Meer stated that it was "fantastic to have this short but sweet lost Half-Life episode on PC at last, and it even has something the PS2 version didn't—online play".
εl/w = (D/H)l/(D/H)w−1 = [(δDl + 1)/(δDw + 1)]−1; where εl/w = net or apparent fractionation, δDl = lipid product and δDw = source water. The δDs of common lipid classes found in living organisms are: n-alkyl: −170‰ ± 50‰ (113‰–262‰ more D-depleted than growth water) isoprenoid: −270‰ ± 75‰ (142‰–376‰ more D-depleted than growth water) phytol: −360‰ ± 50‰ (more depleted than the other two categories) Polyisoprenoid lipids are more depleted than acetogenic (n-alkyl) lipids with more negative δDs.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.